Aurisco released its 2026 interim report. Total operating revenue was 828 million yuan, and net profit attributable to the parent company was 159 million yuan, down 32.42% from the same period last year. Net cash inflow from operating activities was 208 million yuan, down 3.53% year-on-year. The company's asset-liability ratio was 35.85%, gross margin was 54.85%, down 5.26 percentage points from the same period last year, and ROE was 5.93%, down 3.74 percentage points. Diluted earnings per share were 0.39 yuan, down 32.76% year-on-year. The number of shareholders was 13,500, and the top ten shareholders held 78.76% of the total share capital.
Aurisco Pharmaceutical Co LtdNet profit fell 32.42% year-on-year, with lower gross margin and ROE.